Kolkata: The National Pharmaceutical Pricing Authority (NPPA), in an order dated March 27, changed the prices of 80 medicines ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

The Food and Drug Administration (FDA) has expanded the list of medicines for non-communicable diseases (NCDs) exempted from ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE ...

Prolonged exposure to 5 % HCl significantly impacts SS 304's microstructure and mechanical properties, emphasizing the need for effective corrosion protection.

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Roshni Nadar Malhotra, daughter of HCL founder Shiv Nadar, became India's richest woman and the third-richest person overall after acquiring 47% of her father's stake in HCL Corporation and Vama ...